Patient Support Line 1-866-433-8000, Monday - Friday: 8:00 AM to 8:00 PM ET
Frequently Asked Questions
Questions and answers about KISQALI
Click below for answers to some of the most frequently asked questions about KISQALI.
KISQALI is a prescription medicine for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (eBC) with a high risk of coming back. KISQALI is taken with a specific kind of hormone therapy called an aromatase inhibitor (AI).
KISQALI is not chemotherapy. KISQALI is a targeted therapy called a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. By blocking CDK4 and CDK6 proteins, KISQALI can help keep new cancer cells from forming.
KISQALI is a targeted treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (eBC) with a high risk of coming back that blocks, or interferes with, substances that can cause cancer to come back. KISQALI affects cancer cells, but can also affect healthy cells.
Ribociclib (KISQALI) + an aromatase inhibitor (AI) has been proven to significantly reduce the risk of cancer coming back vs an AI alone. Leading cancer experts (the NCCN) recommend ribociclib (KISQALI) + an AI as a treatment option for eligible people with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) stage 2 or stage 3 early breast cancer with a high risk of coming back.
See the proven study results of ribociclib (KISQALI) + an AI
The most common side effects of KISQALI are decreased white blood cell counts, increased liver function tests, decreased red blood cell counts, infections, increased kidney function test, decreased platelet counts, nausea, headache, and tiredness. KISQALI can also cause more serious side effects.
Learn more about the potential side effects of KISQALI.
Your health care team may offer suggestions to help manage some of the side effects of KISQALI. It’s important to talk with your doctor or nurse about side effects you experience and the best ways to manage them.
KISQALI is a prescription medicine that is a convenient once-daily oral tablet that comes in an easy-to-use blister pack. Your doctor will prescribe the dose of KISQALI that's right for you. You should take KISQALI exactly as your health care provider tells you. Take KISQALI each day at about the same time, preferably in the morning. Do not change your dose or stop taking KISQALI unless your health care provider tells you. You may take KISQALI with or without food. Ask your doctor about the recommended dose of your aromatase inhibitor.
If you miss a dose of KISQALI or vomit after taking a dose of KISQALI, do not take another dose on that day. Take your next dose at your regular time.
Avoid eating grapefruit and avoid drinking grapefruit juice. Be sure to share a list of any medications, vitamins, or herbal supplements you are currently taking with your doctor. It's important to make sure all of your medications work safely together.
Novartis Pharmaceuticals Corporation is committed to helping make treatment with KISQALI as affordable as possible.
Novartis Patient Support™ is a comprehensive program to help you start, stay, and save on your KISQALI treatment.
Learn important information and tips on how to work with your doctor to manage potential side effects